drugset / Trial / NCT02562872
DSM265 Prophylaxis of Plasmodium Falciparum Malaria
Phase 1
Completed
24 enrolled
Medicines for Malaria Venture
Center for Infectious Disease Research · collabFred Hutchinson Cancer Center · collabUnited States Department of Defense · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The study is a single centre, randomised, placebo-controlled, double-blind study with DSM265 including up to two cohorts of healthy male and female volunteers aged 18 to 45 years. The study will be conducted into two sequential parts (Cohort 1 and Cohorts 2a and 2b).
Timeline
- Start
- 2016-03
- Primary completion
- 2017-05
- Completion
- 2017-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DSM265 | Small molecule | 400 mg | Oral |
Indications
No indication recorded.